Key result
The transcatheter edge-to-edge valve repair device (TriClip) improved tricuspid regurgitation severity and quality of life compared to medical therapy alone, but demonstrated little impact on all-cause mortality or heart failure hospitalizations at 1 year.
Why the study?
Does transcatheter edge-to-edge valve repair (TEER) improve outcomes in patients with tricuspid regurgitation compared to medical therapy alone?
Systematic Review (n=993)
Does transcatheter edge-to-edge valve repair (TEER) improve outcomes in patients with tricuspid regurgitation compared to medical therapy alone?
TEER for tricuspid regurgitation improves TR severity and quality of life compared to medical therapy, though it does not significantly impact mortality or heart failure hospitalizations and carries a risk of procedural adverse events.
May improve symptoms in tricuspid regurgitation; leaves open effects on mortality and safety in larger trials.
The transcatheter edge-to-edge valve repair (TEER) device (TriClip) might be more effective in reducing tricuspid regurgitation severity and improving quality of life compared to medical therapy alone. The TEER device (TriClip) may have little impact on all-cause mortality, hospitalization due to heart failure, and 6-minute walk tests compared to medical therapy alone. The TEER device (TriClip) demonstrated a numerically higher rate of adverse events than a medical therapy control group in a clinical trial. Patients treated with the TEER device (TriClip) had fewer major adverse events (ranging from 2.5% to 7.1%) than the 10% performance goal in the included clinical trial; common major adverse events included major bleeding, single leaflet device attachment, and nonelective cardiovascular surgery. No device embolization or thrombosis were reported. We did not identify any studies that met our inclusion criteria to evaluate the effectiveness of the TEER device (TriClip) compared to open heart surgery.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2023) conducted a systematic review in Tricuspid Regurgitation (n=993). Transcatheter edge-to-edge valve repair (TriClip) vs. Medical management alone was evaluated on Hierarchical composite of all-cause death, tricuspid-valve surgery, hospitalization for heart failure, and improvement in quality of life (TRILUMINATE Pivotal RCT). The transcatheter edge-to-edge valve repair device (TriClip) improved tricuspid regurgitation severity and quality of life compared to medical therapy alone, but demonstrated little impact on all-cause mortality or heart failure hospitalizations at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: